Selkoe D J
Center for Neurologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
Trends Cell Biol. 1998 Nov;8(11):447-53. doi: 10.1016/s0962-8924(98)01363-4.
It is a truism of modern biomedical science that the development of therapies expected to slow or arrest the progression of a disease requires as detailed an understanding of its molecular and cellular pathogenesis as possible. In turn, the cloning of novel gene products implicated in a disease often leads to new insights about fundamental features of protein structure and function. A particularly compelling example of this beneficial interplay between basic and applied cell biology arises from the exciting recent progress in deciphering Alzheimer's disease (AD). This review discusses the current understanding of the cell biology of two proteins crucial for the pathogenesis of AD, the beta-amyloid precursor protein and presenilin.
现代生物医学科学的一个不言而喻的事实是,开发有望减缓或阻止疾病进展的疗法需要尽可能详细地了解其分子和细胞发病机制。反过来,克隆与疾病相关的新基因产物往往会带来有关蛋白质结构和功能基本特征的新见解。基础细胞生物学与应用细胞生物学之间这种有益相互作用的一个特别引人注目的例子来自于最近在破译阿尔茨海默病(AD)方面取得的令人兴奋的进展。本综述讨论了目前对AD发病机制至关重要的两种蛋白质——β-淀粉样前体蛋白和早老素的细胞生物学的理解。